MAP2K7 and melanoma: Patients with high SEMA6A expression had a significantly reduced median PFS and OS compared with those with low SEMA6A (PFS: 10 months vs. 60 months; Log-Rank p = 0.001; OS: 27.5 months vs. not reached; Log-Rank p = 0.021) (Fig. 6A and B), indicating that SEMA6A might be a good candidate predictor of low efficacy of dual BRAF/MEK inhibition by dabrafenib+trametinib in BRAF-mut melanoma patients.